Vaccine for Japanese encephalitis

Novartis Vaccines has launched Ixiaro for active immunisation of adults against Japanese encephalitis.

Ixiaro, the only vaccine licensed for Japanese encephalitis, is a purified formalin-inactivated whole-virus, cultivated in Vero-cells. Ixiaro should be considered for use in individuals at risk of exposure to Japanese encephalitis through travel or in the course of their occupation.

CLINICAL STUDIES

A study looked at the seroconversion in three dosing schedules: 6 microgram injection on days 0 and 28; 6 microgram injection on day 0; and 12 microgram on day 0. Those who did not receive two doses of the vaccine received placebo on day 28. 97.3% of patients on the two-dose schedule reached seroconversion on day 56 compared to 25.6% in the single 6 microgram group and 41.2% in the single 12 microgram group.1

Another study compared the use of Ixiaro with a previously licensed vaccine to test its immunogenicity; 98% seroconversion was seen in patients who received Ixiario compared to 95% seen in the previously licensed vaccine group.2 There were no serious adverse effects seem in either group with the most common adverse effects including headache, flu-like illness, myalgia and fatigue.2

View Ixiario drug record

REFERENCES

  1. Schuller E et al. Vaccine 2008; 10.1016
  2. Tauber  E et al. Lancet 2007; 370: 1847-53

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases